Is loss of p53 a driver of ductal carcinoma in situ progression?
- PMID: 35764786
- PMCID: PMC9643347
- DOI: 10.1038/s41416-022-01885-5
Is loss of p53 a driver of ductal carcinoma in situ progression?
Abstract
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive carcinoma. Multiple studies have shown that DCIS lesions typically possess a driver mutation associated with cancer development. Mutation in the TP53 tumour suppressor gene is present in 15-30% of pure DCIS lesions and in ~30% of invasive breast cancers. Mutations in TP53 are significantly associated with high-grade DCIS, the most likely form of DCIS to progress to invasive carcinoma. In this review, we summarise published evidence on the prevalence of mutant TP53 in DCIS (including all DCIS subtypes), discuss the availability of mouse models for the study of DCIS and highlight the need for functional studies of the role of TP53 in the development of DCIS and progression from DCIS to invasive disease.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24. Mod Pathol. 2017. PMID: 28338653
-
Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.Cancer Rep (Hoboken). 2020 Jun;3(3):e1248. doi: 10.1002/cnr2.1248. Epub 2020 May 28. Cancer Rep (Hoboken). 2020. PMID: 32671987 Free PMC article.
-
Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution.Mol Oncol. 2009 Jun;3(3):214-9. doi: 10.1016/j.molonc.2009.03.001. Epub 2009 Apr 2. Mol Oncol. 2009. PMID: 19403344 Free PMC article.
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
-
Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.Endocrinology. 2022 Apr 1;163(4):bqac027. doi: 10.1210/endocr/bqac027. Endocrinology. 2022. PMID: 35245349 Free PMC article. Review.
Cited by
-
Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets.Adv Sci (Weinh). 2024 Dec;11(46):e2401041. doi: 10.1002/advs.202401041. Epub 2024 Oct 17. Adv Sci (Weinh). 2024. PMID: 39418072 Free PMC article.
-
Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.Cancer Res Commun. 2025 Jan 1;5(1):138-149. doi: 10.1158/2767-9764.CRC-24-0287. Cancer Res Commun. 2025. PMID: 39723668 Free PMC article.
-
DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges.Cancers (Basel). 2025 Jun 10;17(12):1925. doi: 10.3390/cancers17121925. Cancers (Basel). 2025. PMID: 40563575 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous